Aspartate aminotransferase-to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients
Braz. j. infect. dis
; 12(1): 15-19, Feb. 2008. ilus, graf, tab
Article
in En
| LILACS
| ID: lil-484412
Responsible library:
BR1.1
ABSTRACT
In chronic hepatitis C (CHC), liver biopsy is the gold standard method for assessing liver histology, however it is invasive and can have complications. Non-invasive markers have been proposed and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) has been shown as an easy and inexpensive marker of liver fibrosis. This study evaluated the diagnostic performance of APRI for significant fibrosis and cirrhosis prediction in CHC patients. This study included treatment-naive CHC patients who had undergone liver biopsy from January 2000 to August 2006. All histological slides were reviewed according to the METAVIR system. APRI was calculated based on laboratory results performed within four months from the biopsy. Twenty-eight (56 percent) patients had significant fibrosis (F2-F4) and 13 (26 percent) had cirrhosis (F4). The area under ROC curves of APRI for predicting significant fibrosis and cirrhosis were 0.92 (0.83-1.00) and 0.92 (0.85-1.00), respectively. Using cut-off values recommended by prior studies, significant fibrosis could be identified, in accordance with liver biopsy, in 44 percent and cirrhosis in 66 percent of patients. APRI could identify significant fibrosis and cirrhosis at a high degree of accuracy in studied patients.
Key words
Full text:
1
Index:
LILACS
Main subject:
Aspartate Aminotransferases
/
Hepatitis C, Chronic
/
Alanine Transaminase
/
Clinical Enzyme Tests
/
Liver Cirrhosis
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Braz. j. infect. dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2008
Type:
Article